Equities analysts expect Kezar Life Sciences Inc (NASDAQ:KZR) to post ($0.48) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Kezar Life Sciences’ earnings, with the lowest EPS estimate coming in at ($0.62) and the highest estimate coming in at ($0.40). The business is expected to announce its next quarterly earnings results on Thursday, November 8th.
According to Zacks, analysts expect that Kezar Life Sciences will report full-year earnings of ($2.64) per share for the current year, with EPS estimates ranging from ($3.11) to ($2.10). For the next year, analysts expect that the firm will post earnings of ($2.38) per share, with EPS estimates ranging from ($2.84) to ($2.14). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Kezar Life Sciences.
Kezar Life Sciences (NASDAQ:KZR) last issued its quarterly earnings data on Thursday, August 9th. The company reported ($3.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($2.77).
Several brokerages have issued reports on KZR. Zacks Investment Research downgraded shares of Kezar Life Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, October 24th. Cowen began coverage on shares of Kezar Life Sciences in a research report on Monday, July 16th. They issued an “outperform” rating for the company. Wells Fargo & Co started coverage on shares of Kezar Life Sciences in a research report on Monday, July 16th. They issued an “outperform” rating and a $30.00 price objective for the company. William Blair started coverage on Kezar Life Sciences in a research note on Monday, July 16th. They set an “outperform” rating for the company. Finally, Jefferies Financial Group started coverage on Kezar Life Sciences in a research note on Monday, July 16th. They set a “buy” rating and a $23.00 target price for the company. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $26.50.
Several institutional investors have recently added to or reduced their stakes in the company. Laurion Capital Management LP bought a new position in Kezar Life Sciences during the second quarter worth $173,000. BlackRock Inc. bought a new position in Kezar Life Sciences during the second quarter worth $173,000. MYDA Advisors LLC bought a new position in Kezar Life Sciences during the second quarter worth $213,000. Dean Capital Investments Management LLC bought a new position in Kezar Life Sciences during the second quarter worth $585,000. Finally, Prosight Management LP bought a new position in Kezar Life Sciences during the second quarter worth $721,000. Institutional investors own 42.19% of the company’s stock.
Shares of NASDAQ:KZR opened at $24.96 on Friday. Kezar Life Sciences has a 52-week low of $14.77 and a 52-week high of $26.86.
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Read More: Cash Flow Analysis in Stock Selection
Get a free copy of the Zacks research report on Kezar Life Sciences (KZR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.